Fallopian Tube Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Fallopian Tube Cancer – Pipeline Review, H2 2016’, provides an overview of the Fallopian Tube Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer

The report reviews pipeline therapeutics for Fallopian Tube Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Fallopian Tube Cancer therapeutics and enlists all their major and minor projects

The report assesses Fallopian Tube Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Acetylon Pharmaceuticals, Inc.

Adaptimmune Therapeutics Plc

Aduro BioTech, Inc.

Advenchen Laboratories, LLC

Amgen Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

Atara Biotherapeutics, Inc.

Bayer AG

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Celldex Therapeutics, Inc.

Celsion Corporation

Cerulean Pharma, Inc.

Clovis Oncology, Inc.

Critical Outcome Technologies Inc.

CTI BioPharma Corp.

Dr. Reddy's Laboratories Limited

EirGenix Inc.

Eisai Co., Ltd.

Eli Lilly and Company

Esperance Pharmaceuticals, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Galena Biopharma, Inc.

Ganymed Pharmaceuticals AG

Gene Techno Science Co., Ltd.

Genentech, Inc.

Genor BioPharma Co Ltd

Glycotope GmbH

Gradalis Inc.

Ignyta, Inc.

Immune Design Corp.

ImmunoGen, Inc.

Immunovaccine, Inc.

Incyte Corporation

Innate Pharma S.A.

Johnson & Johnson

Juno Therapeutics Inc.

Karyopharm Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

Lee's Pharmaceutical Holdings Limited

Mabion SA

MabVax Therapeutics Holdings, Inc.

Mateon Therapeutics Inc

MedImmune, LLC

Medivation, Inc.

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals Inc

MolMed S.p.A.

Mycenax Biotech Inc.

Novartis AG

OBI Pharma, Inc.

Oncobiologics, Inc.

Oncolix, Inc.

Oncolytics Biotech Inc.

OncoMed Pharmaceuticals, Inc.

Ono Pharmaceutical Co., Ltd.

Oxford BioMedica Plc

Pharma Mar, S.A.

PsiOxus Therapeutics Limited

Quest PharmaTech Inc.

Richter Gedeon Nyrt.

Samyang Holdings Corporation

Sanofi Pasteur SA

Sellas Inc

Shenzen SiBiono GeneTech Co., Ltd.

Sotio a.s.

TapImmune Inc.

Tara Immuno-Oncology Therapeutics LLC

Tesaro, Inc.

TetraLogic Pharmaceuticals

Tyrogenex, Inc.

Vascular Biogenics Ltd.

VentiRx Pharmaceuticals, Inc.

Vyriad Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Fallopian Tube Cancer Overview 7

Therapeutics Development 8

Fallopian Tube Cancer - Therapeutics under Development by Companies 10

Fallopian Tube Cancer - Therapeutics under Investigation by Universities/Institutes 16

Fallopian Tube Cancer - Pipeline Products Glance 17

Fallopian Tube Cancer - Products under Development by Companies 21

Fallopian Tube Cancer - Products under Investigation by Universities/Institutes 27

Fallopian Tube Cancer - Companies Involved in Therapeutics Development 28

Fallopian Tube Cancer - Therapeutics Assessment 106

Drug Profiles 133

Fallopian Tube Cancer - Discontinued Products 657

Fallopian Tube Cancer - Product Development Milestones 658

Appendix 664

List of Tables

List of Tables

Number of Products under Development for Fallopian Tube Cancer, H2 2016 20

Number of Products under Development for Fallopian Tube Cancer – Comparative Analysis, H2 2016 21

Number of Products under Development by Companies, H2 2016 23

Number of Products under Development by Companies, H2 2016 (Contd..1) 24

Number of Products under Development by Companies, H2 2016 (Contd..2) 25

Number of Products under Development by Companies, H2 2016 (Contd..3) 26

Number of Products under Development by Companies, H2 2016 (Contd..4) 27

Number of Products under Investigation by Universities/Institutes, H2 2016 28

Comparative Analysis by Late Stage Development, H2 2016 29

Comparative Analysis by Clinical Stage Development, H2 2016 30

Comparative Analysis by Early Stage Development, H2 2016 31

Comparative Analysis by Unknown Stage Development, H2 2016 32

Products under Development by Companies, H2 2016 33

Products under Development by Companies, H2 2016 (Contd..1) 34

Products under Development by Companies, H2 2016 (Contd..2) 35

Products under Development by Companies, H2 2016 (Contd..3) 36

Products under Development by Companies, H2 2016 (Contd..4) 37

Products under Development by Companies, H2 2016 (Contd..5) 38

Products under Investigation by Universities/Institutes, H2 2016 39

Fallopian Tube Cancer – Pipeline by AbbVie Inc, H2 2016 40

Fallopian Tube Cancer – Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 41

Fallopian Tube Cancer – Pipeline by Adaptimmune Therapeutics Plc, H2 2016 42

Fallopian Tube Cancer – Pipeline by Aduro BioTech, Inc., H2 2016 43

Fallopian Tube Cancer – Pipeline by Advenchen Laboratories, LLC, H2 2016 44

Fallopian Tube Cancer – Pipeline by Amgen Inc., H2 2016 45

Fallopian Tube Cancer – Pipeline by Astex Pharmaceuticals, Inc., H2 2016 46

Fallopian Tube Cancer – Pipeline by AstraZeneca Plc, H2 2016 47

Fallopian Tube Cancer – Pipeline by Atara Biotherapeutics, Inc., H2 2016 48

Fallopian Tube Cancer – Pipeline by Bayer AG, H2 2016 49

Fallopian Tube Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 50

Fallopian Tube Cancer – Pipeline by Boston Biomedical, Inc., H2 2016 51

Fallopian Tube Cancer – Pipeline by Celldex Therapeutics, Inc., H2 2016 52

Fallopian Tube Cancer – Pipeline by Celsion Corporation, H2 2016 53

Fallopian Tube Cancer – Pipeline by Cerulean Pharma, Inc., H2 2016 54

Fallopian Tube Cancer – Pipeline by Clovis Oncology, Inc., H2 2016 55

Fallopian Tube Cancer – Pipeline by Critical Outcome Technologies Inc., H2 2016 56

Fallopian Tube Cancer – Pipeline by CTI BioPharma Corp., H2 2016 57

Fallopian Tube Cancer – Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 58

Fallopian Tube Cancer – Pipeline by EirGenix Inc., H2 2016 59

Fallopian Tube Cancer – Pipeline by Eisai Co., Ltd., H2 2016 60

Fallopian Tube Cancer – Pipeline by Eli Lilly and Company, H2 2016 61

Fallopian Tube Cancer – Pipeline by Esperance Pharmaceuticals, Inc., H2 2016 62

Fallopian Tube Cancer – Pipeline by Exelixis, Inc., H2 2016 63

Fallopian Tube Cancer – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 64

Fallopian Tube Cancer – Pipeline by Galena Biopharma, Inc., H2 2016 65

Fallopian Tube Cancer – Pipeline by Ganymed Pharmaceuticals AG, H2 2016 66

Fallopian Tube Cancer – Pipeline by Gene Techno Science Co., Ltd., H2 2016 67

Fallopian Tube Cancer – Pipeline by Genentech, Inc., H2 2016 68

Fallopian Tube Cancer – Pipeline by Genor BioPharma Co Ltd, H2 2016 69

Fallopian Tube Cancer – Pipeline by Glycotope GmbH, H2 2016 70

Fallopian Tube Cancer – Pipeline by Gradalis Inc., H2 2016 71

Fallopian Tube Cancer – Pipeline by Ignyta, Inc., H2 2016 72

Fallopian Tube Cancer – Pipeline by Immune Design Corp., H2 2016 73

Fallopian Tube Cancer – Pipeline by ImmunoGen, Inc., H2 2016 74

Fallopian Tube Cancer – Pipeline by Immunovaccine, Inc., H2 2016 75

Fallopian Tube Cancer – Pipeline by Incyte Corporation, H2 2016 76

Fallopian Tube Cancer – Pipeline by Innate Pharma S.A., H2 2016 77

Fallopian Tube Cancer – Pipeline by Johnson & Johnson, H2 2016 78

Fallopian Tube Cancer – Pipeline by Juno Therapeutics Inc., H2 2016 79

Fallopian Tube Cancer – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 80

Fallopian Tube Cancer – Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 81

Fallopian Tube Cancer – Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 82

Fallopian Tube Cancer – Pipeline by Mabion SA, H2 2016 83

Fallopian Tube Cancer – Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016 84

Fallopian Tube Cancer – Pipeline by Mateon Therapeutics Inc, H2 2016 85

Fallopian Tube Cancer – Pipeline by MedImmune, LLC, H2 2016 86

Fallopian Tube Cancer – Pipeline by Medivation, Inc., H2 2016 87

Fallopian Tube Cancer – Pipeline by Merck & Co., Inc., H2 2016 88

Fallopian Tube Cancer – Pipeline by Merck KGaA, H2 2016 89

Fallopian Tube Cancer – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 90

Fallopian Tube Cancer – Pipeline by MolMed S.p.A., H2 2016 91

Fallopian Tube Cancer – Pipeline by Mycenax Biotech Inc., H2 2016 92

Fallopian Tube Cancer – Pipeline by Novartis AG, H2 2016 93

Fallopian Tube Cancer – Pipeline by OBI Pharma, Inc., H2 2016 94

Fallopian Tube Cancer – Pipeline by Oncobiologics, Inc., H2 2016 95

Fallopian Tube Cancer – Pipeline by Oncolix, Inc., H2 2016 96

Fallopian Tube Cancer – Pipeline by Oncolytics Biotech Inc., H2 2016 97

Fallopian Tube Cancer – Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016 98

Fallopian Tube Cancer – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 99

Fallopian Tube Cancer – Pipeline by Oxford BioMedica Plc, H2 2016 100

Fallopian Tube Cancer – Pipeline by Pharma Mar, S.A., H2 2016 101

Fallopian Tube Cancer – Pipeline by PsiOxus Therapeutics Limited, H2 2016 102

Fallopian Tube Cancer – Pipeline by Quest PharmaTech Inc., H2 2016 103

Fallopian Tube Cancer – Pipeline by Richter Gedeon Nyrt., H2 2016 104

Fallopian Tube Cancer – Pipeline by Samyang Holdings Corporation, H2 2016 105

Fallopian Tube Cancer – Pipeline by Sanofi Pasteur SA, H2 2016 106

Fallopian Tube Cancer – Pipeline by Sellas Inc, H2 2016 107

Fallopian Tube Cancer – Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H2 2016 108

Fallopian Tube Cancer – Pipeline by Sotio a.s., H2 2016 109

Fallopian Tube Cancer – Pipeline by TapImmune Inc., H2 2016 110

Fallopian Tube Cancer – Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 111

Fallopian Tube Cancer – Pipeline by Tesaro, Inc., H2 2016 112

Fallopian Tube Cancer – Pipeline by TetraLogic Pharmaceuticals, H2 2016 113

Fallopian Tube Cancer – Pipeline by Tyrogenex, Inc., H2 2016 114

Fallopian Tube Cancer – Pipeline by Vascular Biogenics Ltd., H2 2016 115

Fallopian Tube Cancer – Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 116

Fallopian Tube Cancer – Pipeline by Vyriad Inc, H2 2016 117

Assessment by Monotherapy Products, H2 2016 118

Number of Products by Stage and Target, H2 2016 120

Number of Products by Stage and Mechanism of Action, H2 2016 131

Number of Products by Stage and Route of Administration, H2 2016 142

Number of Products by Stage and Molecule Type, H2 2016 144

Fallopian Tube Cancer – Dormant Projects, H2 2016 665

Fallopian Tube Cancer – Dormant Projects (Contd..1), H2 2016 666

Fallopian Tube Cancer – Dormant Projects (Contd..2), H2 2016 667

Fallopian Tube Cancer – Dormant Projects (Contd..3), H2 2016 668

Fallopian Tube Cancer – Discontinued Products, H2 2016 669

List of Figures

List of Figures

Number of Products under Development for Fallopian Tube Cancer, H2 2016 20

Number of Products under Development for Fallopian Tube Cancer – Comparative Analysis, H2 2016 21

Number of Products under Development by Companies, H2 2016 22

Number of Products under Investigation by Universities/Institutes, H2 2016 28

Comparative Analysis by Late Stage Development, H2 2016 29

Comparative Analysis by Clinical Stage Development, H2 2016 30

Comparative Analysis by Early Stage Products, H2 2016 31

Assessment by Monotherapy Products, H2 2016 118

Number of Products by Top 10 Targets, H2 2016 119

Number of Products by Stage and Top 10 Targets, H2 2016 119

Number of Products by Top 10 Mechanism of Actions, H2 2016 130

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 130

Number of Products by Top 10 Routes of Administration, H2 2016 141

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 141

Number of Products by Top 10 Molecule Types, H2 2016 143

Number of Products by Stage and Top 10 Molecule Types, H2 2016 143

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports